secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eiger BioPharmaceuticals, Inc. (—)
CIK:        0001305253
Form:       8-K
Filed at:   2024-09-04T23:59:59+00:00
Accession:  0001193125-24-212606
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 2.01
LLM model:  deepseek-v4-flash:cloud@v2

Eiger sells lonafarnib ($5.2M) and peginterferon lambda ($1M) assets in Ch11; closings Sept 3
--------------------------------------------------------------------------------

- Bankruptcy Court approved both asset sales on August 20, 2024; closings occurred September 3, 2024.
- Lonafarnib antiviral assets sold to Eiger InnoTherapeutics for $5.2M plus cure costs and assumed liabilities.
- Peginterferon lambda-1a assets sold to same buyer for $1.0M plus cure costs and assumed liabilities.
- Company warns securityholders may face significant or total loss on investment given Chapter 11 outcome.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/0001193125-24-212606-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1305253/000119312524212606/d889209d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-212606

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer